Taxotere® Chemotherapy Drug & Permanent Hair Loss

If you were treated with Taxotere and suffered permanent hair loss, call today!

If you or a loved one was prescribed chemotherapy to treat breast cancer, and experienced hair loss that appears to be permanent rather than temporary, we encourage you to get in touch with the attorneys at Spangenberg Shibley & Liber today, because you may be entitled to compensation.

Recommended Reading:

Facts About Taxotere

Taxotere (Docetaxel) is an antimicrotubular antineoplastic agent, a type of chemotherapy indicated for “the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy,” among other uses.

The U.S. Food and Drug Administration (FDA) approved docetaxel for treating women with operable node-positive breast cancer in August 2004. Many women treated with Taxotere reported that they suffered permanent hair loss. Allegations are currently being investigated that suggest the manufacturer of Taxotere, Sanofi-Aventis, should have known about the disfiguring side effect to their drug, yet failed to warn of the increased risk of permanent alopecia.

Twice As Potent, No More Effective

In 2009, the FDA wrote a letter to Sanofi-Aventis stating, “This reprint carrier is false or misleading because it presents unsubstantiated superiority claims and overstates the efficacy of Taxotere. Therefore, this material misbrands the drug in violation of the Federal Food, Drug, and Cosmetic Act.”

The FDA also stated in its 2009 letter that, although Taxotere is twice as potent as an alternative chemotherapy drug, it has been observed to have comparable efficacy. Many women suffered permanent hair loss after being treated with Taxotere, all the while there was an equally effective and arguably safer alternative drug available.

Taxotere Reportedly Linked to Permanent Alopecia

In December 2015, the FDA announced a safety labeling change to Taxotere (docetaxel). It reads, “Cases of permanent alopecia have been reported.”

Another recent study, published in the Oxford Journal’s Annals of Oncology, concluded that “Permanent and severe alopecia is a newly reported complication of the FEC 100–docetaxel breast cancer regimen.”

You can take action today!

If you or someone you love developed permanent baldness/alopecia as a result of chemotherapy treatment, we encourage you to contact Spangenberg Shibley & Liber today for a free review of your legal rights and options. You may be entitled to compensation. Learn more today!

Call (216) 600-0114 or fill out our free online form to get started.